Loading
Pooling 2,148 women from nine studies showed that every extra 10% of immune cells in the tumour stroma cut the risk of relapse by about 13%, and node-negative patients with 30% or more had a 97% chance of being free of distant relapse at three years.
Individual data from 2,148 early TNBC patients in nine studies treated with anthracycline-based chemotherapy with or without taxanes were pooled; stromal TILs were scored the same way in each. Average sTILs were 23% (SD 20%) and 77% had 1% or more; sTILs were lower with older age, larger tumours, nodal involvement and lower grade. In multivariable models sTILs added independent prognostic information for invasive disease-free, distant disease-free and overall survival; each 10% increment gave hazard ratios of 0.87, 0.83 and 0.84. In node-negative patients with sTILs 30% or more, three-year iDFS was 92%, D-DFS 97% and OS 99%.
TILs are the strongest cheap prognostic biomarker in early TNBC, scored on a standard slide, and the basis of the de-escalation trials that omit chemotherapy in small, lymphocyte-rich tumours.
Shares Sherene Loi, Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Sherene Loi, Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).